甲磺酸伊马替尼治疗43例慢性粒细胞白血病进展期患者的疗效观察

目的:探讨甲磺酸伊马替尼(STI571,格列卫)治疗慢性粒细胞白血病(CML)进展期(即加速期、急变期)患者的临床疗效。方法:43例疾病进展期CML患者口服格列卫治疗,评价其血液学、细胞遗传学及分子遗传学疗效。结果:43例患者的完全血液学反应(CHR)率、完全细胞遗传学反应(CCyR)率和完全分子遗传学反应(CMR)率分别为44.2%、30.0%和21.9%,观察期内总病死率为25.6%,均于12个月内死亡,不同年龄(≤25岁,>25岁)患者之间病死率有统计学意义(P<0.05)。结论:格列卫对慢性粒细胞白血病进展期患者有一定的疗效,但耐药现象较普遍,年轻患者的预后可能较差。

Observation on the therapeutic effects of imatinib mesylate in treatment of 43 cases with advanced chronic myelogenous leukemia

Objective： To investigate the effects of imatinib mesylate in treatment of advanced chronic myelogenous leukemia. Methods ： To observe the hematologic, eytogenetie and molecular genetic effect of Gleevic in treatment of 43 ca- ses with advanced chronic myelogenous leukemia. Results： The complete hematologic response, complete cytogenetic re- sponse and complete molecular genetic response was 44.2% , 30.0% and 21.9% , respectively. Total mortality during ob- servation was 25.6% , and those were dead in 12 months. There was statistically difference in different ages （ ≤25 yeas and 〉 25 years）. Conclusions： Gleevic had effects in patients with advanced chronic myelogenous leukemia, but the drug resistance is common, and young patients might have bad prognosis.